老年患者用药安全:现状与改进建议
老年患者是药物的主要使用者,且异质性强,不应仅以年龄定义而应按衰弱分层。老年人药代与药效特征独特、常多病共存并接受多药治疗,不良反应症状非特异易被误认为老年综合征。衰弱老年人在临床试验中代表性不足,其用药获益-风险平衡常不明确。本文提出促进衰弱老年人入组试验及监测治疗以减少不良反应的策略。
要点
- 老年患者应按衰弱分层而非仅按年龄定义。
- 衰弱老年人常被排除在临床试验外,用药获益-风险未知。
- 药物警戒报告应聚焦衰弱而非年龄,可用合并症数量作替代指标。
核心结论
- 老年患者不宜仅以年龄定义,应基于衰弱进行分层,且衰弱老年人用药的获益-风险平衡常不明确。
研究设计与样本
- 本文为综述性文章,未报告系统检索范围与样本量。
主要发现
- 老年患者药代与药效特征独特、常多病共存并接受多药治疗。
- 老年人不良反应症状非特异,易被误认为老年综合征而难以识别。
- 衰弱老年人在临床试验中代表性不足,其药理反应与预期治疗结局可能不同于非衰弱患者。
关键数值与推荐
- 药物-药物及药物-疾病相互作用的自动警示应仅标记有临床意义的相互作用。
- 药品剂型应便于剂量调整,包装与标签应顾及衰弱老年人的身体与认知限制。
- 药物警戒汇总报告应总结老年人群安全性特征,并聚焦衰弱而非按年龄呈现结果;无衰弱信息时可用合并症数量作为替代指标。
临床怎么用
- 对衰弱老年患者应关注非特异症状,警惕被误认为老年综合征的不良反应。
- 使用药物相互作用自动警示时仅采纳有临床意义的提示以支持合理处方。
- 选择便于剂量调整的剂型,并确保包装与标签适配衰弱老年人的身体与认知能力。
局限性
- 本文未报告系统检索范围与样本量,证据基础未在摘要中说明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Elderly patients are the main users of drugs and they differ from younger patients. They are a heterogeneous population that cannot be defined only by age but should rather be stratified based on their frailty. The elderly have distinctive pharmacokinetic and pharmacodynamic characteristics, are frequently polymorbid, and are therefore treated with multiple drugs. They may experience adverse reactions that are difficult to recognize, since some of them present non-specific symptoms easily mistaken for geriatric conditions. Paradoxically, the elderly are underrepresented in clinical trials, especially the frail individuals whose pharmacological response and expected treatment outcome can be different from those of non-frail patients. This means that the benefit-risk balance of drugs used in frail elderly patients is frequently unknown. We present some proposals to overcome the barriers preventing the enrollment of frail elderly patients in clinical trials, and strategies for monitoring their therapy to minimize the risk of adverse reactions. Automated alerts for drug and drug-disease interactions could help appropriate prescribing but should flag only clinically relevant interactions. Pharmaceutical forms should be designed to allow easy dose adjustment and, together with packaging and labeling, should account for the physical and cognitive limitations of frail elderly patients. Aggregate pharmacovigilance reports should summarize the safety profile in the elderly, but rather than presenting the results by age they should focus on patients' frailty, perhaps using the number of comorbidities as a proxy when information on frailty is not available.
引用
- Furlan G, Caduff-Janosa P, Sottosanti L, et al. Drug Safety in Geriatric Patients: Current Status and Proposed Way Forward. Drug Saf. 2020. PMID: 32500271. doi:10.1007/s40264-020-00949-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。